絞り込み

16530

広告

大飯原発訴訟 住民側が上告断念 敗訴確定へ

福井県にある大飯原子力発電所3号機と4号機について、住民らが関西電力に運転しないよう求めた裁判で、住民側は、17日、最高裁判所に上告しない方針を明らかにしました...

  1. 西日本豪雨の災害ごみ、中川環境相「広域処...
  2. ジェームズ・ウェッブ宇宙望遠鏡、今年2度...
  3. 版画・彫刻家の浜田知明さん死去 戦争テー...
  4. 俳優の生田悦子さん死去 (NHK)

ニュース一覧

スターを付ける スターを付ける     (44view , 0users)

Full Text Sources

Osteoporosis is the most widespread skeletal disease requiring innovative therapeutic strategies for its management. The understanding of receptor activator of nuclear factor kappa-B ligand (RANKL) and sclerostin's role in bone cell biology is completely changing the therapeutic landscape. RANKL supports osteoclast formation and activity and is mainly produced by cells of osteoblastic lineage. Sclerostin, an antagonist of the Wnt pathway, has a key role in bone formation and is mainly secreted by osteocytes. High levels of RANKL and sclerostin have been detected in osteoporosis, leading to the production of antibodies able to neutralize their activity. Areas covered: In this review, the authors give an overview and discuss the literature and data on denosumab and romosozumab to treat osteoporosis. Clinical studies indicate that long-term treatment with denosumab causes a continuous increase in bone mineral density with low incidence of adverse effects. Romosozumab treatment gives increases bone formation and improves bone mineral density (BMD) though further studies are needed to better evaluate the adverse effects. Expert opinion: Denosumab and romosozumab show promise in the treatment of osteoporosis. Furthermore, their different mechanisms of action compared to existing anti-osteoporotic drugs may permit alternative strategies for osteoporosis treatment down the line.
PMID: 29113523 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード